Valantine Hannah

Director Valantine Hannah sold 25,484 shares (77.3% of holdings) for $1.72M at $67.41 avg; stock now -19.2% from 52-week high.

Valantine Hannah executed 2 separate sales totaling 25,484 shares for $1,717,780.84 on 2026-02-27, selling at a blended average price of $67.41 while the stock now trades at $64.53, down 16.5% over 30 days and 13.0% over 90 days. The sale reduced her holdings from 32,949 shares to 7,465 shares, a 77.3% reduction. This is particularly significant given that BridgeBio remains unprofitable with a net income of $-184,937,000.00 over the most recent full fiscal year, and the stock is trading 19.2% below its 52-week high. Hannah's prior sell at this ticker on 2025-11-12 was followed by positive returns at both 30 and 90 days, indicating that timing was not favorable for that transaction, though this current filing provides no forward-looking timing indicator yet.

Director Valantine Hannah sold 25,484 shares of BBIO at $66.07 on 2025-11-12, reducing stake by 77.3% to 7,465 shares ($1.7M value).

Valantine Hannah, a director of BridgeBio Pharma, executed a substantial sale of 25,484 shares (77.3% reduction in holdings) at $66.07, leaving a minimal remaining position of 7,465 shares. The company is unprofitable with negative net income of $-184,937,000.00 in its most recent full fiscal year, despite strong revenue growth of 2285.3% year-over-year and recent quarterly revenue of $120,700,000.00. The transaction occurred near the 52-week high of $66.62 and followed a notable 30-day price increase of 17.2%, positioning this as a near-peak sale by a director who has substantially diminished insider holdings. The dramatic reduction in stake—from 32,949 to 7,465 shares—warrants investor scrutiny regarding the director's confidence in the company's trajectory, particularly given the persistent unprofitability despite accelerating revenue.